<DOC>
	<DOCNO>NCT00003322</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different way may kill tumor cell . It yet know whether intravenous two-drug combination chemotherapy effective intravenous intraperitoneal infusion three-drug combination chemotherapy treat primary peritoneal stage III epithelial ovarian cancer . PURPOSE : Randomized phase III trial compare effectiveness intravenous two-drug combination chemotherapy intravenous intraperitoneal three-drug combination chemotherapy treat patient primary peritoneal stage III epithelial ovarian cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Primary Peritoneal Stage III Epithelial Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare pathological response , recurrence-free interval , survival patient optimal stage III epithelial ovarian cancer primary peritoneal carcinoma receive intravenous ( IV ) paclitaxel cisplatin v IV paclitaxel intraperitoneal ( IP ) cisplatin plus IP paclitaxel . II . Compare toxic effect complication 2 treatment regimen patient . III . Determine frequency prognostic significance BRCA1 BRCA2 mutation patient . IV . Determine effect non-genetic risk factor course disease BRCA1- BRCA2-related ovarian cancer primary peritoneal carcinoma . V. Compare quality life patient receive treatment . OUTLINE : This randomize study . Patients stratify accord gross residual disease ( present v absent ) whether second-look surgery perform end treatment ( yes v ) . Blood drawn BRCA mutation analysis DNA extraction start chemotherapy , randomization . Patients randomize one two treatment arm . Patients arm I receive IV paclitaxel 24-hour infusion day 1 follow IV cisplatin day 2 . Patients arm II receive IV paclitaxel 24-hour infusion day 1 follow intraperitoneal ( IP ) cisplatin day 2 , plus IP paclitaxel day 8 . Treatment arm repeat every 3 week total 6 treatment course . Following chemotherapy , second look surgery perform select patient . Quality-of-life assessment perform prior randomization , prior course 4 , 3-6 week completion course 6 prior second look surgery select , 6 month treatment complete , 12 month treatment complete . Patients follow every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 384 patient accrue study within 16 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primary peritoneal carcinoma optimal ( great 1 cm residual disease ) stage III epithelial ovarian carcinoma follow epithelial cell type : Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell carcinoma Malignant Brenner 's Tumor Adenocarcinoma NOS Prior surgery ovarian/peritoneal carcinoma require No epithelial ovarian carcinoma low malignant potential ( borderline carcinoma ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Alkaline phosphatase great 3 time normal No acute hepatitis Renal : Creatinine great 2.0 mg/dL Cardiovascular : No unstable angina No myocardial infarction within prior 6 month Patients abnormal cardiac conduction eligible disease stable least 6 month Other : No septicemia severe infection No severe gastrointestinal bleeding No invasive malignancy within past 5 year except nonmelanoma skin cancer Any previous cancer treatment must contraindicate protocol therapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics No 6 week since prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>